Clinical Trial Update: Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating potential additive inhibition of the HPA axis when ciclesonide nasal spray is used with orally inhaled beclomethasone dipropionate in p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Perennial Allergic Rhinitis

Drugs mentioned

• Beclomethasone dipropionate (HFA-BDP) (beclomethasone dipropionate)
• Ciclesonide nasal spray (ciclesonide)

Snippet

Sponsor: AstraZeneca | Conditions: Rhinitis, Allergic, Perennial | Phase 3 | Status: COMPLETED